These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2019017)

  • 1. Pharmacokinetics of active vitamins D3, 1 alpha-hydroxyvitamin D3 and 1 alpha, 25-dihydroxyvitamin D3 in patients on chronic hemodialysis.
    Kimura Y; Nakayama M; Kuriyama S; Watanabe S; Kawaguchi Y; Sakai O
    Clin Nephrol; 1991 Feb; 35(2):72-7. PubMed ID: 2019017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating 1 alpha,25-dihydroxyvitamin D levels after a single dose of 1 alpha,25-dihydroxyvitamin D3 or 1 alpha-hydroxyvitamin D3 in normal men.
    Seino Y; Tanaka H; Yamaoka K; Yabuuchi H
    Bone Miner; 1987 Sep; 2(6):479-85. PubMed ID: 3505770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma vitamin D metabolite concentrations in chronic renal failure: effect of oral administration of 25-hydroxyvitamin D3.
    Halloran BP; Schaefer P; Lifschitz M; Levens M; Goldsmith RS
    J Clin Endocrinol Metab; 1984 Dec; 59(6):1063-9. PubMed ID: 6333430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioligand receptor assay for 25-hydroxyvitamin D2/D3 and 1 alpha, 25-dihydroxyvitamin D2/D3.
    Hughes MR; Baylink DJ; Jones PG; Haussler MR
    J Clin Invest; 1976 Jul; 58(1):61-70. PubMed ID: 1084355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of 24R,25-dihydroxyvitamin D3 in combination with 1 alpha-hydroxyvitamin D3 in predialysis renal insufficiency: biochemistry and histomorphometry of cancellous bone.
    Birkenhäger-Frenkel DH; Pols HA; Zeelenberg J; Eijgelsheim JJ; Schot R; Nigg AL; Weimar W; Mulder PG; Birkenhäger JC
    J Bone Miner Res; 1995 Feb; 10(2):197-204. PubMed ID: 7754799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of effects of 1 alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man.
    Brickman AS; Coburn JW; Friedman GR; Okamura WH; Massry SG; Norman AW
    J Clin Invest; 1976 Jun; 57(6):1540-7. PubMed ID: 932193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination.
    Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Eade Y; Johnson JR; George CR; Collett P
    Miner Electrolyte Metab; 1985; 11(6):358-68. PubMed ID: 3877862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D3 metabolites in chronic renal failure and after renal transplantation.
    Lucas PA; Woodhead JS; Brown RC
    Nephrol Dial Transplant; 1988; 3(1):70-6. PubMed ID: 3132643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A trial of suppressing secondary hyperparathyroidism by oral high dose therapy of 1, 25-dihydroxyvitamin D3].
    Shigematsu T; Kawaguchi Y; Unemura S; Suzuki M; Yamamoto H; Morita T; Momose M; Ogawa A; Nakayama M; Miyahara T
    Nihon Jinzo Gakkai Shi; 1989 Apr; 31(4):393-401. PubMed ID: 2787433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between 1alpha(OH)D3 and 1,25(OH)2D3 on the suppression of plasma PTH levels in uremic patients, evaluated by the 'whole' and 'intact' PTH assays.
    Brandi L; Egfjord M; Olgaard K
    Nephron Clin Pract; 2005; 99(4):c128-37. PubMed ID: 15722644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronotherapy of high-dose 1,25-dihydroxyvitamin D3 in hemodialysis patients with secondary hyperparathyroidism: a single-dose study.
    Tsuruoka S; Sugimoto K; Ohmori M; Kawaguchi A; Saito T; Fujimura A
    Clin Pharmacol Ther; 1999 Dec; 66(6):609-16. PubMed ID: 10613617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observation on the use of 1 alpha-hydroxyvitamin D3 in the prevention of bovine parturient paresis: the effect of a single injection on plasma 1 alpha-hydroxyvitamin D3, 1,25-dihydroxyvitamin D3, calcium, and hydroxyproline.
    Bar A; Perlman R; Sachs M
    J Dairy Sci; 1985 Aug; 68(8):1952-8. PubMed ID: 3840185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of 1 alpha-hydroxycholecalciferol after intraperitoneal, intravenous and oral administration in patients undergoing peritoneal dialysis.
    Joffe P; Cintin C; Ladefoged SD; Rasmussen SN
    Clin Nephrol; 1994 Jun; 41(6):364-9. PubMed ID: 8076440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis.
    Brandi L; Daugaard H; Tvedegaard E; Storm T; Olgaard K
    Nephron; 1989; 53(3):194-200. PubMed ID: 2797340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The oral 1-25 dihydroxyvitamin D3 pulse therapy in hemodialysis patients for the early treatment of secondary hyperparathyroidism].
    Kawabe M; Shimizu M; Takeuchi M; Matsunobu S; Hayama N; Iino Y; Hara K; Terashi A
    Nihon Jinzo Gakkai Shi; 1992 Jul; 34(7):807-11. PubMed ID: 1479720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained osteoblast nuclear receptor binding of converted 1alpha, 25-dihydroxyvitamin D3 after administration of 3H-1alpha-hydroxyvitamin D3: a combined receptor autoradiography and radioassay time course study with comparison to 3H-1alpha, 25-dihydroxyvitamin D3.
    Koike N; Ichikawa F; Nishii Y; Stumpf WE
    Calcif Tissue Int; 1998 Nov; 63(5):391-5. PubMed ID: 9799823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic inhibition of tumor promoter-induced ornithine decarboxylase in 1 alpha-hydroxyvitamin D3-treated animals.
    Hashiba H; Fukushima M; Chida K; Kuroki T
    Cancer Res; 1987 Oct; 47(19):5031-5. PubMed ID: 3621189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-alpha-hydroxyvitamin D3 in chronic renal failure. A potent analogue of the kidney hormone, 1,25-dihydroxycholecalciferol.
    Chan JC; Oldham SB; Holick MF; DeLuca HF
    JAMA; 1975 Oct; 234(1):47-52. PubMed ID: 1174223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective biological response by target organs (intestine, kidney, and bone) to 1,25-dihydroxyvitamin D3 and two analogues.
    Norman AW; Sergeev IN; Bishop JE; Okamura WH
    Cancer Res; 1993 Sep; 53(17):3935-42. PubMed ID: 8395333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.